Comparison of Allergy Prevalence between Brimonidine/Timolol Fixed Combination and 0.15% Brimonidine in Glaucoma Patients
10.3341/jkos.2018.59.5.451
- Author:
Eun Jung PARK
1
;
Yeoun Sook CHUN
Author Information
1. Department of Ophthalmology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. yschun100@hanmail.net
- Publication Type:Original Article
- Keywords:
Glaucoma;
Korean;
Ocular allergy;
0.2% brimonidine/0.5% timolol fixed combination;
0.15% brimonidine
- MeSH:
Brimonidine Tartrate;
Compliance;
Glaucoma;
Humans;
Hypersensitivity;
Incidence;
Medical Records;
Patient Education as Topic;
Prevalence;
Retrospective Studies;
Timolol
- From:Journal of the Korean Ophthalmological Society
2018;59(5):451-458
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the allergy prevalence and clinical manifestations of 0.2% brimonidine/0.5% timolol fixed combination (BTFC) and 0.15% brimonidine in Korean patients with glaucoma. METHODS: We retrospectively analyzed the medical records of 196 glaucoma patients treated with BTFC and 234 glaucoma patients treated with 0.15% brimonidine. We compared sex, age, type of glaucoma, treatment period, allergy history, onset time of ocular allergy and clinical characteristics of allergy in the two groups. RESULTS: Ocular allergy percentages 10.14% in the BTFC group and 22.02% in the 0.15% brimonidine group, and the risk of allergy was approximately 0.4 times lower in patients using BTFC (hazard ratio = 2.5, p = 0.009). The BTFC group developed ocular allergy at a mean of 20.5 months (range: 1.7–51.1 months), and the 0.15% brimonidine group developed ocular allergy at a mean of 7.7 months (range: 0.4–50.8 months). In the BTFC group, 50% of the ocular allergy occurred within 15 months, and within 5 months in the 0.15% brimonidine group. Clinical characteristics of brimonidine allergy involved two types of conjunctival follicles and conjunctival papillae, but there were no significant differences in incidence according to allergy type (p = 0.566). CONCLUSIONS: The prevalence of ocular allergy in the BTFC group was lower than that in the 0.15% brimonidine group in Korean patients with glaucoma. The results of this study are expected to be useful for patient education and compliance improvement using brimonidine.
